You have 9 free searches left this month | for more free features.

Non-Hodgkin Lymphomas (NHL)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)

Recruiting
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Jan 25, 2023

B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma
  • +4 more
  • (no location specified)
Dec 7, 2022

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))

Completed
  • Lymphoma Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • Nagoya, Aichi, Japan
  • +12 more
Feb 21, 2022

Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) Trial in Tianjin (Ex-vivo expanded allogeneic ?dT cells)

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • Peripheral T Cell Lymphoma (PTCL)
  • Ex-vivo expanded allogeneic γδT cells
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Disease Hospital
Jan 5, 2021

B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

Active, not recruiting
  • B-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Birmingham, Alabama
  • +23 more
Dec 2, 2022

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +86 more
Jan 23, 2023

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

Non-Hodgkin Lymphoma Trial in Milano (Romiplostim)

Completed
  • Non-Hodgkin Lymphoma
  • Milano, Italy
    Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 10, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)

Recruiting
  • Epstein-Barr Virus Infections
  • +3 more
  • Nivolumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

NHL, Adult Trial in Zhengzhou, Shanghai, Nanyang (APG-1252, Chidamide)

Recruiting
  • NHL, Adult
  • Zhengzhou, Henanan, China
  • +3 more
Jul 27, 2022

B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)

Recruiting
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • UCART20x22
  • CLLS52
  • Austin, Texas
    Sarah Cannon - St. David South Austin Medical Center
Dec 8, 2022

Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • Perth, Western Australia, Australia
    Linear Clinical Research Ltd
Apr 20, 2023

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023